View | Modify | Create | Collaborate
Boston Scientific stock (NYSE:BSX) lost more than 42% – dropping from $45 at the beginning of 2020 to below $26 in late March 2020 – then spiked 73% to around $45 now (through the end of July 2021). That means it has fully recovered to the pre-pandemic levels.
Why? While the Covid-19 outbreak and associated lockdowns resulted in an uncertain outlook for the broader markets, the multi-billion-dollar Fed stimulus announced in late March 2020 helped the markets stage a strong recovery. Further, with economies opening up gradually, the elective surgeries that were deferred earlier in 2020 are now getting attended to, though there is a huge backlog. As such, demand for Boston Scientific's products will likely pick up over the coming quarters.
Boston Scientific's revenues surged 54% (y-o-y) to $3.1 billion in Q2 2021, with revenue growth seen across all major segments. While the Cardiovascular segment saw a 51% rise in sales, MedSurg and Rhythm & Neuro saw a large 65% growth each. Note that Q2 2020 was the worst affected quarter for elective surgeries. As such, the Q2 2021 revenue compared favorably over the last year quarter's very low sales figure. The adjusted EPS came in at $0.40 vs $0.08 in the prior year quarter, reflecting a 5x rise, due to revenue growth and margin expansion.
Boston Scientific announced 10 acquisitions over the last year or so. Recently, the company closed the acquisition of spine solutions maker Vertiflex for an upfront cash payment of $465 million, and also the BTG plc acquisition, which added $220 million to the company's top line in 2020. In June 2021, Boston Scientific acquired the remaining 73% stake in Farapulse Inc. for a $295 million upfront payment, and possible $92 million in milestone payments. The company expects these acquisitions to aid its long-term growth.
Boston Scientific unveiled its medium to long term growth strategy, targeting double-digit adjusted earnings growth, driven by margin improvements. The company aimed for an organic revenue CAGR of 6-9% during the 2020-2022 time frame. However, this plan was laid before the pandemic, and the company's estimates will have to be adjusted given the impact of the pandemic. Also, with over 40% of the U.S. population fully vaccinated for Covid-19 by the end of May 2021, the sales are expected to rebound, which will also result in margin expansion.
Boston Scientific's stock has been on a strong run. It saw around 35% growth in 2018, and it was up 29% in 2019. The company's earnings growth has aided the stock price move over the recent years.
Below are key drivers of Boston Scientific's value that present opportunities for upside or downside to the current Trefis price estimate for the company's stock:
Founded in 1979, The Boston Scientific Corporation develops, manufactures, and supplies medical devices across the world. These devices are primarily sold in the following areas of medicine - Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology/Women's Health, Neuromodulation, and Electrophysiology. The company's largest sources of revenue are sales of Interventional Cardiology and Cardiac Rhythm Management devices.
Boston Scientific supplies its devices in around 125 countries around the world, mainly the U.S., Europe, the Middle East, Japan, Canada, China, India, and Brazil. The company historically has been very acquisitive in order to strategically expand its operations and sales.
Its main competitors are Johnson & Johnson, Medtronic, and Abbott.
Interventional Cardiology, Endoscopy, and Cardiac Rhythm Management are the major sources of revenue for the company. Here's why:
Coronary stents are implantable tubes which help in opening blocked arteries and ensuring smooth blood flow. These are the largest revenue driver for Boston Scientific as it is the only company in the world to provide a two-drug platform. The company keeps launching improved versions of these stents to maintain its market leadership position. Following the same trend, the company launched Promus PREMIER Element, an improved version of its drug-eluting stent (DES) technology in 2013 along with the next generation line of defibrillators and pacemakers. Continuous innovation and product improvement should allow Boston Scientific to maintain a healthy market share and increase its revenue base from the division, in our view.
Acquisitions have always been an integral part of Boston Scientific's growth strategy. In 2011, the company acquired Sadra Medical and Atritech in order to increase the market share of its respective structural heart therapy and atrial fibrillation businesses, which fall in the Interventional Cardiology division. It also acquired Cameron Health which has strengthened the sales of its Cardiac Rhythm Management business.
Boston Scientific spends a significant portion of its revenues on research and development. As a result it has been able to launch many self-manufactured products in the market. In the last few years, the company has launched a few new devices in its major segments. For instance, the company launched its RESONATE™ cardiac resynchronization therapy defibrillator (CRT-D) systems in Europe in 2017, and it has been fueling defibrillator growth.
Following its historical acquisition strategy, Boston Scientific has acquired several companies in the last few years in order to expand its product portfolio. Most recently in 2018, the company acquired NXThera for $406 million. It also acquired BTG plc, and Millipede Inc over the recent years.
Boston Scientific is undertaking a restructuring program which aims to improve efficiency and innovation. This should help improve its market presence while also cutting costs, benefiting margins.
Stringent healthcare regulations have implemented checks on the pricing structure of medical device companies, which could have a negative impact on global revenue growth.